ONCOLOGY Vol 26 No 8 | Oncology

Which Rectal Cancers Are Locally Advanced?

August 20, 2012

In populations in whom there has been a focus on the important components of rectal cancer management, 5-year survival is better in rectal cancer than in colon cancer, which was not the case in the past. Total mesorectal excision (TME) is one of many important components of current management.

Quackery, Placebos, and Other Thoughts: An Integrative Oncologist’s Perspective

August 20, 2012

As they say, “absence of evidence is not evidence of absence.” Many alternative therapies, once believed by conventional medical practitioners to be merely placebos, have now been shown to have proven therapeutic value (eg, acupuncture, numerous botanical extracts, meditation).

Acute Myeloid Leukemia With Adverse Cytogenetic Risk

August 03, 2012

Acute myeloid leukemia (AML) encompasses multiple disease entities that differ with regard to marrow morphology, cytochemistry, immunophenotype, pretreatment clinical characteristics, and treatment outcome.

Going Beyond Systemic Fluoropyrimidines With Radiation Therapy for Rectal Cancer: What Should Be the Priority?

August 20, 2012

As we look forward, we suggest that the priority should be to further our understanding of the tumor’s interactions with its microenvironment and with the immune system. We think that such an understanding will be critical for advances in locally advanced rectal cancer therapy.

The Natural History of Hormone Receptor–Positive Breast Cancer: Attempting to Decipher an Intriguing Concept

August 10, 2012

It is time to develop more active treatments in the early-disease setting that actually eradicate ER-positive breast cancer before new mutations and secondary resistance have a chance to develop. In this regard, standard chemotherapy is not the answer.